New targeted radiation shows promise for Tough-to-Treat prostate cancer
NCT ID NCT07562438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a low-dose radioactive drug (177Lu-P17-088) that targets a protein called PSMA on prostate cancer cells. It is for people with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The goal is to see if the treatment can shrink tumors and slow disease progression while keeping side effects manageable. About 20 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?